Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Literature
1.
Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, et al. Clinical guide SEOM: hepatocellular carcinoma. Clin Trans Oncol. 2015;17:988–95.CrossRef
2.
Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;40:900–9.CrossRef
3.
Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32:2847–54.CrossRefPubMedPubMedCentral
4.
Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong R, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631–9.CrossRefPubMed
5.
Wahl, Stenmark MH, Tao Y, Pollom E, Caoili E, Lawrence T, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34:452–9.CrossRefPubMed
Metadata
Title
Clinical guide SEOM: hepatocellular carcinoma (HCC): considerations on SBRT
Authors
F. Arias
G. Asín
A. Viúdez
Publication date
01-09-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1501-5

Other articles of this Issue 9/2016

Clinical and Translational Oncology 9/2016 Go to the issue

Research Article

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient

Review Article

Braf V600E mutation in melanoma: translational current scenario

Research Article

Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells

Research Article

Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients

Research Article

Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients

Research Article

Paediatric tumour boards in Spain: a national survey
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits